findmyKOL

Paul Gurbel, MD

Enriched profile

Director, Sinai Center for Thrombosis Research and Drug Development · Sinai Hospital of Baltimore

ORCID↗NPI↗
✓ Full profile
Region🇺🇸 Baltimore, MD · Northeast · United StatesSpecialtyCardiovascular DiseaseFocusCoronary Artery Disease / ACS
Active KOLfindmyKOL type: EliteLatest publication2026Online presenceverified 2026Payments2021–2025NIH fundingNone on fileWhy? →

Paul Gurbel is Director, Sinai Center for Thrombosis Research and Drug Development at Sinai Hospital of Baltimore. OpenAlex indexes 828 publications with 36,898 citations (h-index 81); ClinicalTrials.gov lists 19 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Cardiovascular Disease profiles in the findmyKOL directory.

Data verified 14 Aug 2026

Overview

Updated 14 Oct 2026

Paul A. Gurbel, MD, is Director, Sinai Center for Thrombosis Research and Drug Development at Sinai Hospital of Baltimore / LifeBridge Health. The public record shows 828 publications with 36,898 citations (h-index 81), centered on Coronary Artery Disease / ACS. It also documents an investigator role on 19 registered clinical trials, industry payments reported by 42 companies.

  • Most recent indexed publication: 2026 · Arteriosclerosis, thrombosis, and vascular biology
  • Top research focus: Coronary Artery Disease / ACS
  • 19 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 42 companies

Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Coronary Artery Disease / ACS13 trialsCoronary Artery Disease12 trialsMyocardial Infarction3 trialsInfarction3 trialsType 2 Diabetes1 trialObesity1 trialHypertension1 trialDyslipidemia / Lipid Disorders1 trialStroke1 trialOverweight1 trialPeripheral Arterial Disease1 trialPrediabetic State1 trialST Elevation Myocardial Infarction1 trialNon-ST Elevated Myocardial Infarction1 trialRheumatoid Arthritis1 trialCardiovascular Diseases1 trialVascular Diseases1 trialAngina, Stable1 trialHeart Failure1 trialCOVID-191 trial

Research focus

OpenAlex concept fingerprint
Coronary Artery Disease / ACS

Drugs & molecules

across trials, industry payments and publications
Xareltogeneric · RivaroxabanClinical trials—Industry payments26Publications1Eliquisgeneric · ApixabanClinical trials—Industry payments10Publications1Verquvogeneric · VericiguatClinical trials—Industry payments35Publications—Leqviogeneric · InclisiranClinical trials—Industry payments34Publications—Entrestogeneric · Sacubitril / valsartanClinical trials—Industry payments26Publications—Repathageneric · EvolocumabClinical trials—Industry payments21Publications—Wegovygeneric · SemaglutideClinical trials—Industry payments20Publications—Nexletolgeneric · Bempedoic acidClinical trials—Industry payments14Publications—Vyndaqelgeneric · TafamidisClinical trials—Industry payments12Publications—Brilintageneric · TicagrelorClinical trials—Industry payments9Publications—Jardiancegeneric · EmpagliflozinClinical trials—Industry payments9Publications—Vascepageneric · Icosapent ethylClinical trials—Industry payments9Publications—

Works with

trial sponsors and companies reporting payments
Novartis Pharmaceuticals CorporationClinical trials—Industry payments55Janssen Pharmaceuticals, IncClinical trials—Industry payments26Abbott LaboratoriesClinical trials—Industry payments25Amgen Inc.Clinical trials—Industry payments22Merck Sharp & Dohme LLCClinical trials—Industry payments20Pfizer Inc.Clinical trials—Industry payments20Novo Nordisk IncClinical trials—Industry payments18ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)Clinical trials—Industry payments17AstraZeneca Pharmaceuticals LPClinical trials—Industry payments16Boehringer Ingelheim Pharmaceuticals, Inc.Clinical trials—Industry payments15Esperion Therapeutics, Inc.Clinical trials—Industry payments14LifeBridge HealthClinical trials10Industry payments—Alnylam Pharmaceuticals Inc.Clinical trials—Industry payments9Amarin Pharma Inc.Clinical trials—Industry payments9Kestra Medical Technology Services, Inc.Clinical trials—Industry payments9Merck Sharp & Dohme CorporationClinical trials—Industry payments8Scpharmaceuticals Inc.Clinical trials—Industry payments7Bayer HealthCare Pharmaceuticals Inc.Clinical trials—Industry payments5Kowa Pharmaceuticals America, Inc.Clinical trials—Industry payments4Regeneron Healthcare Solutions, Inc.Clinical trials—Industry payments4Boston Scientific CorporationClinical trials—Industry payments3Inova Health Care ServicesClinical trials3Industry payments—Kiniksa Pharmaceuticals International, plcClinical trials—Industry payments3Kiniksa Pharmaceuticals, Ltd.Clinical trials—Industry payments3AstraZenecaClinical trials2Industry payments—Atricure, Inc.Clinical trials—Industry payments2Baxter HealthcareClinical trials—Industry payments2BridgeBio Pharma, Inc.Clinical trials—Industry payments2E.R. Squibb & Sons, L.L.C.Clinical trials—Industry payments2Medtronic, Inc.Clinical trials—Industry payments2

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
828publications

Distinct works indexed by OpenAlex, matched via ORCID; 20 in PubMed.

36,898citations

Total citations across indexed works.

81h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
19clinical trials

Investigator role on registered studies.

View trials ↓
42companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
0NIH grants

Federally funded research awards.

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 14 Oct 2026

Listed as an investigator on 19 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 14 Oct 2026

42 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cardiovascular

    89.8%
    Statin27.9%
    Atorvastatin Calcium56%Rosuvastatin Calcium37%Pravastatin Sodium5%Simvastatin2%
    Part D<11 patients
    Beta blocker17.9%
    Metoprolol Succinate55%Carvedilol19%Metoprolol Tartrate16%Atenolol5%Nebivolol Hcl3%Labetalol Hcl3%
    Part D<11 patients

    + 13 more classes in this area

  • Blood & clotting

    10.2%
    Factor Xa inhibitor5.9%
    Eliquis77%Xarelto23%
    Part D≥31 patients
    P2Y12 inhibitor4.3%
    Clopidogrel63%Brilinta37%
    Part D≥24 patients
Where care is delivered (Part B)9.6% facility · 90.4% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →

Publications

Updated 14 Oct 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Online presence

Updated 14 Oct 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/paul-gurbel-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
  • LinkedIn

    linkedin.com/in/paul-gurbel-238143287

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗
  • ResearchGate

    researchgate.net/profile/Paul-Gurbel

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗

Mentions by others

where others cite or feature them
  • Facebook

    facebook.com/CBSBaltimore/videos/ask-a-doc-heart-health/1293465537694421

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →facebook.com ↗
  • YouTube

    youtube.com/watch

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
  • YouTube

    youtube.com/watch

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 14 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • Board Certified

    Internal Medicine

    1986
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doctors.lifebridgehealth.org ↗
  • M.D.

    University of Maryland School of Medicine

    1983
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →scholars.duke.edu ↗
  • Board Certified

    Cardiovascular Disease

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doctors.lifebridgehealth.org ↗
  • Board Certified

    Interventional Cardiology

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doctors.lifebridgehealth.org ↗

Editorial & leadership roles

journal and society appointments
  • Director

    Sinai Center for Thrombosis Research and Drug Development

    1997
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →thedailyrecord.com ↗
  • Editorial Board Member

    Journal of the American College of Cardiology (JACC)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doctors.lifebridgehealth.org ↗
  • Editorial Board Member

    Journal of the Royal Society of Medicine (Cardiovascular Disease)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doctors.lifebridgehealth.org ↗
  • Editorial Board Member

    Journal of Thrombosis and Thrombolysis (Coronary and Structural Heart Disease section)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →link.springer.com ↗

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution
  • Adjunct Professor

    Department of Medicine, Duke University School of Medicine

    2013
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →scholars.duke.edu ↗
  • Professor of Medicine

    Johns Hopkins University School of Medicine

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →inovaheart.org ↗
  • Director

    Interventional Cardiology and Cardiovascular Medicine Research, Inova Center for Thrombosis Research and Drug Development, Inova Heart and Vascular Institute

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →inovanewsroom.org ↗

Media & interviews

press, podcasts and appearances

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.